What are King Pharmaceuticals's total assets?

King Pharmaceuticals (KG) holds $964.2M in total assets.

How much debt does King Pharmaceuticals have?

King Pharmaceuticals carries $176.7M in total debt against $121.4M of shareholders' equity, a debt-to-equity ratio of 1.46.

How much cash does King Pharmaceuticals have?

King Pharmaceuticals holds $62.2M in cash and equivalents.

Where does King Pharmaceuticals's balance sheet data come from?

Every line is extracted from King Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

King Pharmaceuticals KG Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25
Cash and cash equivalents	$62.21M+1,724%	$24.63M—	$40.52M—	$33.67M—
Restricted cash	$47.16M—	$9.15M—	$27.63M—	$14.72M—
Assets held for sale	$8.93M—	——	——	——
Trading assets	——	——	——	——
Accrued investment income	$4.87M—	——	——	——
Derivative assets	——	——	——	——
Premiums receivable	$297K—	——	——	——
Operating lease right-of-use assets	——	——	——	——
Goodwill	$8.51M—	——	——	——
Other non-current assets	$17.64M—	——	——	——
Equity method investments	$113.8M—	——	——	——
Long-term investments	$339.34M—	——	——	——
Available-for-sale securities	$37.23M—	——	——	——
Allowance for credit losses	——	——	——	——
Equity securities	$11.75M—	——	——	——
Reinsurance recoverables	$436.38M—	——	——	——
Total assets	$964.23M—	——	——	——
Operating lease liabilities, current	$2M—	——	——	——
Liabilities held for sale	$401K—	——	——	——
Accrued interest	$644K—	——	——	——
Unearned premiums	$16.89M—	——	——	——
Long-term debt	$174.72M—	——	——	——
Operating Lease Liabilities (Total)	$2M—	——	——	——
Reserve for insurance claims	$314.15M—	——	——	——
Total liabilities	$842.79M—	——	——	——
Common stock	42.5M—	——	——	——
Additional paid-in capital	$178.98M—	——	——	——
Retained earnings	-$6.23M—	——	——	——
Accumulated other comprehensive income (loss)	$537K—	——	——	——
Treasury stock	$51.95M—	——	——	——
Total stockholders' equity	$121.44M+2,773%	$128.28M—	$143.77M—	$150.09M—
Total liabilities and stockholders' equity	$964.23M—	——	——	——
Available-for-Sale Debt Securities - Amortized Cost	——	——	——	——
Available-for-Sale Debt Securities - Amortized Cost (Due Within One Year)	——	——	——	——
Available-for-Sale Debt Securities - Fair Value by Maturity	——	——	——	——
Available-for-Sale Debt Securities - Single Maturity Date	——	——	——	——
Total Cash, Cash Equivalents, and Restricted Cash (Inclusive)	——	——	——	——
Current Equity Amortized Cost	$11.15M—	——	——	——
Equity Securities (FV-NI) - Cost Basis	$11.15M—	——	——	——
Available-for-Sale Debt Securities - Fair Value (Maturing 1 to 5 Years)	——	——	——	——
Alternative Investments Fair Value	——	——	——	——
Contingent Consideration Asset	——	——	——	——
Equity Amortized Cost	$11.15M—	——	——	——
Goodwill and Intangible Assets, Net	$8.51M—	——	——	——
Investments - Amortized Cost Basis	$118.3M—	——	——	——
Investments - Cost Basis	$11.15M—	——	——	——
Net Investment in Lease	$1.97M—	——	——	——
Net Operating Loss Carryforwards	$88.7M—	——	——	——
Equity method investments	——	——	——	——
Goodwill and intangible assets, net	$8.51M—	——	——	——
Investments	$339.34M—	——	——	——
Operating lease right-of-use assets	$1.97M—	——	——	——
Other Assets	$17.64M—	——	——	——
Operating Lease Right-of-Use Assets in Other Assets	$1.97M—	——	——	——
Other Investments	$175.67M—	——	——	——
Liability for Claims and Claims Adjustment Expense	$593.35M—	——	——	——
Derivative Liabilities - Fair Value	——	——	——	——
Reserve for Incurred But Not Reported (IBNR) Claims	$314.15M—	——	——	——
Lease Liability Payments - 2020 (Remaining Three Months)	——	——	——	——
Operating Lease Liability Payments - 2024 (Lessee)	——	——	——	——
Operating Lease Liability Payments - 2025 (Lessee)	——	——	——	——
Lease Liability Payments - Due Year Two	——	——	——	——
Lease Liability Payments - Due Year Three	——	——	——	——
Lease Liability Payments - Due Year Four	——	——	——	——
Lease Liability Payments - Remainder of Fiscal Year	——	——	——	——
Contingent Consideration Liability (Non-Current)	$0—	——	——	——
Debt Maturity - 5 to 10 Years	——	——	——	——
Debt - Unamortized Discount (Premium) and Issuance Costs, Net	$87.64M—	——	——	——
Operating Lease Liability Payments - 2026 (Lessee)	——	——	——	——
Operating Lease Liability Payments - 2027 (Lessee)	——	——	——	——
Operating Lease Liability Payments - 2028 (Lessee)	——	——	——	——
Accrued expenses and other liabilities	$57.43M—	——	——	——
Total debt	$176.72M—	——	——	——
Total Carrying Value of Debt	$262.36M—	——	——	——
Common Stock Par Value Per Share	$0.01—	——	——	——
Common Stock Shares Issued	10.1M—	——	——	——
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$101K—	——	——	——
Shares Reserved for Future Issuance Under Stock Plans	——	——	——	——
Unrealized Gains on Investments	$562K—	——	——	——
Unrealized Losses on Investments (Before Tax)	$484K—	——	——	——
Cumulative Cost Basis	$118.3M—	——	——	——
Fair Value Measurement Disclosure	——	——	$144.31M—	——
Gross Assets/Liabilities	——	——	——	——
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	$484K—	——	——	——
Gross Unrealized Gains	$562K—	——	——	——
Total	$118.3M—	——	——	——
Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10	——	——	——	——
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10	——	——	——	——
Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five	——	——	——	——
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five	——	——	——	——
Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost	——	——	——	——
Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One	——	——	——	——
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One	——	——	——	——
Available for sale investments	$118.38M—	——	——	——
Business Combination, Contingent Consideration, Liability	$0—	——	——	——
Cash and cash equivalents, end of period	——	——	——	——
Number of votes per share	——	——	——	——
Common stock, par value (in dollars per share)	$0.01—	——	——	——
Common stock, shares authorized (in shares)	——	——	——	——
Common stock, shares issued (in shares)	$10.11M—	——	——	——
Common Stock, Shares, Outstanding	$7.82M—	——	——	——
Long-term debt, gross	$262.36M—	——	——	——
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net	$87.64M—	——	——	——
Debt Securities, Available-for-Sale, Allowance for Credit Loss	——	——	——	——
Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration	$88.7M—	——	——	——
Net operating loss carryforwards, with no expiry date, percentage	——	——	——	——
Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration	$387.59M—	——	——	——
Derivative Liability	——	——	——	——
Net unrealized losses on held for sale AFS investments	——	——	——	——
Equity method investments (Note 11)	$113.8M—	——	——	——
% of Total	——	——	——	——
Cost	$11.15M—	——	——	——
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value	——	——	$144.31M—	——
Amortized cost	——	——	——	——
Fixed Maturities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	——	——	——	——
Fixed Maturities, Continuous Unrealized Loss Position, Fair Value	——	——	——	——
Less than 12 Months	——	——	——	——
12 Months or More	——	——	——	——
Fixed Maturities, Continuous Unrealized Loss Position, Accumulated Loss	——	——	——	——
Fixed Maturities, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss	——	——	——	——
Fixed Maturities, Fair Value	——	——	——	——
% of Total fair value	——	——	——	——
Number of securities in an unrealized loss position	——	——	——	——
Assets held in trust accounts, reinsurance agreements	$7.45M—	——	——	——
Estimated recovery amount, maximum	——	——	——	——
Less: change in cash and cash equivalents held for sale	——	——	——	——
Insurance liabilities net	——	——	——	——
Unrealized losses of unrealized loss positions	——	——	——	——
Fair value of unrealized loss positions	——	——	——	——
Investments, Gross Unrealized Gain (Loss), Net of Deferred Income Tax Expense	——	——	——	——
Net unrealized gains on fixed maturity investments	——	——	——	——
Lessee, Operating Lease, Liability, Fair Value Discount	——	——	——	——
Thereafter	——	——	——	——
Liability for Unpaid Claims and Claims Adjustment Expense, Net	$156.97M—	——	——	——
Insurance	$279.2M—	——	——	——
Loans And Leases Receivable Related Parties	$78.61M—	——	——	——
Percentage of outstanding debt holders in lawsuit (at least)	——	——	——	——
Number of directors	——	——	——	——
Number of independent directors	——	——	——	——
Operating Lease Weighted Average Discount Rate Percent	——	——	——	——
Other Commitment	$72.18M—	——	——	——
% of Total	——	——	——	——
As a percentage of total assets	——	——	——	——
Insurance and reinsurance balances receivable, valuation allowance	$14K—	——	——	——
Collateral by third party	——	——	——	——
Reinsurance recoverable for paid and unpaid claims and claims adjustments, adverse development cover	——	——	——	——
Reinsurance recoverable on unpaid losses and loss expenses	$436.38M—	——	——	——
Valuation allowance for uncollectible reinsurance	$1.93M—	$1.74M—	$1.46M—	——
Restricted Cash and Investments	$159.5M—	——	——	——
Restricted Investment, Net of Liabilities	——	——	——	——
Incentive stock program, shares reserved for future grants (in shares)	——	——	——	——
Shares reserved for awards to employees and outside directors (in shares)	——	——	——	——
Treasury stock, shares (in shares)	$2.28M—	——	——	——
Purchase Obligation	$72.18M—	——	——	——
Remainder of Fiscal Year 2024	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about King Pharmaceuticals.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are King Pharmaceuticals's total assets?: King Pharmaceuticals (KG) holds $964.2M in total assets.
How much debt does King Pharmaceuticals have?: King Pharmaceuticals carries $176.7M in total debt against $121.4M of shareholders' equity, a debt-to-equity ratio of 1.46.
How much cash does King Pharmaceuticals have?: King Pharmaceuticals holds $62.2M in cash and equivalents.
Where does King Pharmaceuticals's balance sheet data come from?: Every line is extracted from King Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.